Videos

Branch explains the evolving understanding of the role genetic variants play in driving hepatic steatosis and associated cardiovascular risk or protection.

This segment of Maloney’s interview at the SDPA Fall Conference discussed off-label uses of JAK inhibitors and other treatment news in dermatology.

Phase 3 LIBERTY AIMS data reveal significant reductions in nasal polyps, surgery, and steroid use in patients with AFRS, a challenging CRSwNP subtype.

Maloney speaks in this interview at the SDPA Fall Conference about off-label uses of JAK inhibitors in dermatology.

Dupilumab maintained histologic and endoscopic improvements across all pediatric age groups with EoE, according to Joshua Wechsler, MD.

Dale Lee, MD, told HCPLive that regular monitoring and potential psychosocial support are important to help children with celiac disease maintain a gluten-free diet.

At ACAAI 2025, Shaker dispels epinephrine myths, emphasizing that it is safe, effective, and underused in anaphylaxis care.

At ACAAI 2025, Shaker highlighted evolving therapies and real-world barriers that continue to limit optimal anaphylaxis management.

The SDPA president, Sarah Vicari, spoke at the 2025 SDPA Fall Conference about the conference and its significance.

At ACAAI 2025, Durban breaks down natural allergy treatments and separates myths from evidence.

Shroff emphasizes the need to address more than just liver health in patients with alcohol-associated liver disease and reviews trends in AUD pharmacotherapy prescriptions.

Cheung explores the effect of sparsentan on urinary biomarkers in treatment-naive patients with IgA nephropathy.

Ahead of ACAAI 2025, HCPLive spoke with Chovatiya on challenges in translating these promising immunologic targets into real-world clinical practice.

At ACAAI 2025, HCPLive spoke with Chovatiya on the OX40/OX40L pathway and what makes it an attractive therapeutic target over other established pathways.

Julie Khlevner, MD, AGAF, highlights that FDA approval of linaclotide provides the first pharmacologic therapy for pediatric IBS-C.

This segment of Goff’s SDPA Fall 2025 interview features a discussion of dietary changes and sunscreen use as a means to improve skin health.

In this interview at SDPA Fall 2025, Goff highlights several takeaways from her session on lifestyle and diet choices among patients in the dermatology space.

Thomas Wallach, MD, discusses phase 3 safety data of tenapanor in pediatric patients with IBS-C, presented at the 2025 NASPGHAN Annual Meeting.

Jonathan Barratt, MBChB, PhD, discusses 36-week atacicept data from ASN Kidney Week 2025.

FDA-approved RBL shows 95% success and sustained microbiome restoration in recurrent C. difficile.

New 48-month results from the phase 3 extension also showed greater macula and retina preservation in patients treated earlier.

Multicenter data presented by Silvana Bonilla, MD, at NASPGHAN 2025 highlight regional variation in pediatric H. pylori prevalence and support selective biopsy practices guided by clinical suspicion.

A multicenter study from NASPGHAN 2025 highlights geographic and immune-driven variations in pediatric H. pylori infection across the Americas.

Kwatra spoke at Fall Clinical about several key highlights from his sessions discussing atopic dermatitis, prurigo nodularis, and the OX40 ligand (OX40L).

In his Fall Clinical interview, Chovatiya highlights several key takeaways from his talk on generalized pustular psoriasis (GPP) management.

Susan Corbridge, PhD, and Alanna Kavannagh, MSN, CCRN, discuss the role of advanced practice providers on the evolving pulmonary and critical care teams during CHEST 2025.

Gabryszewski said new data confirm early introduction guidelines are working, showing real-world declines in peanut allergy.

Research reveals a significant skin-brain connection, linking inflammatory skin diseases to neurocognitive and emotional health, particularly in children with atopic dermatitis.